Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SALT: Ranibizumab vs Aflibercept in Wet AMD
NCT01958918Phase 4Completed
- Sponsor
- Novartis
- Start
- Oct 2013
- Primary completion
- Nov 2016
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 10
01
Overview
A Phase 4 trial of ranibizumab in neovascular age-related macular degeneration (NVAMD), sponsored by Novartis. Started Oct 2013; status: completed.
02
Drugs
ranibizumab
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT01958918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01958918.